Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 16/20 | 0.46 |
| ▸ | DRD2 | P14416 | 11/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1881004 | 0.86 | DRD3 (0.44) | DRD3DRD2KCNH2CHRM1CHRM3 | |
| SCHEMBL23465893 | 0.72 | DRD2 (0.56) | DRD3DRD2KCNH2CHRM1CHRM3 | |
| SCHEMBL20547943 | 0.71 | MFN2 (0.46) | DRD3 | |
| SCHEMBL4872348 | 0.66 | PDE1B (0.38) | DRD3DRD2KCNH2CHRM1CHRM3 | |
| SCHEMBL1877559 | 0.66 | — | — | |
| SCHEMBL21045569 | 0.65 | MFN2 (0.54) | DRD3DRD2PDE1C | |
| SCHEMBL17712756 | 0.65 | PRKDC (0.39) | DRD3DRD2KCNH2CHRM1CHRM3 | |
| SCHEMBL17712727 | 0.64 | MEN1 (0.64) | DRD3DRD2KCNH2CHRM1CHRM3 | |
| SCHEMBL18488318 | 0.63 | DRD2 (0.53) | DRD3DRD2KCNH2CHRM1CHRM3 | |
| SCHEMBL1874141 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| CN-107108597-B | Dopamine D3 receptor antagonist compounds | 英立维尔英国有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
| US-10239870-B2 | Dopamine D3 receptor antagonists | INDIVIOR UK LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-10239870-B2 | Dopamine D3 receptor antagonists | INDIVIOR UK LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-20180282318-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS | INDIVIOR UK LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2017-11-23 | — | — | US | disclosed |
| EP-3212637-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | Indivior UK Limited (GB) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016067043-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2016-05-06 | — | — | WO | disclosed |
| US-7947683-B2 | 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMTED (GB) | 2011-05-24 | — | — | US | disclosed |
| US-7947683-B2 | 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMTED (GB) | 2011-05-24 | — | — | US | disclosed |
| US-7947683-B2 | 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMTED (GB) | 2011-05-24 | — | — | US | disclosed |
| US-20090124629-A1 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-20090124629-A1 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-20090124629-A1 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| WO-2006108701-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282318-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS | DRD3, DRD2, DRD4 | DRD3 1/4885DRD2 2/4885KCNH2 1476/4885 |
| US-20090124629-A1 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, HTR3C, TACR2 | DRD3 1/4885DRD2 11/4885KCNH2 220/4885 |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | DRD3 1/4885DRD2 2/4885KCNH2 1283/4885 |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | DRD3 1/4885DRD2 2/4885KCNH2 1283/4885 |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | DRD3 1/4885DRD2 2/4885KCNH2 1283/4885 |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | DRD3 1/4885DRD2 2/4885KCNH2 1283/4885 |
| US-10239870-B2 | Dopamine D3 receptor antagonists | DRD3, DRD2, DRD4 | DRD3 1/4885DRD2 2/4885KCNH2 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.